Orchid Pharma Limited has informed the Exchange about Transcript
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma reported FY25 sales of Rs. 922 crore, up 13% YoY, with EBITDA of Rs. 156 crore versus Rs. 140 crore last year. Q4 FY25 sales were Rs. 237 crore (up 9% YoY) with EBITDA of Rs. 40 crore. Volume growth was strong at 18-20% YoY. Management guided for a muted FY26 due to ongoing pricing pressure, the Rs. 9 crore EBITDA drag from the newly launched AMS (antimicrobial solutions) division, and CAPEX ramp-up for the 7-ACA facility. The 7-ACA project has been delayed by 6 months, with mechanical completion now expected by December 2026 and first commercial product in March 2027. The Cefiderocol project remains on track for validation batches in late 2026 and commercial launch in Q2 CY2027. Enmetazobactam (sold as Orblicef in India with Cipla) exceeded expectations, reaching 10,000 patients in just six months. NCLT has cleared the merger of Dhanuka Laboratories into Orchid, with the combined entity expected to generate over Rs. 1,500 crore in revenue and Rs. 175 crore in EBITDA. Allecra's insolvency filing in Germany clouds US commercialization of Enmetazobactam, and management is evaluating legal options.
Near-term outlook is cautious with a muted FY26 expected, but management expressed confidence that margins have bottomed out and reaffirmed its mid-teen margin aspiration. The Dhanuka merger and key product launches (Enmetazobactam ramp-up, Cefiderocol in 2027) provide longer-term growth visibility, while the Allecra insolvency and 7-ACA delay pose execution and revenue risks.